Search company, investor...

Parthenon Therapeutics

Founded Year



Series A | Alive

Total Raised


Last Raised

$65M | 2 yrs ago

About Parthenon Therapeutics

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Headquarters Location

One Broadway

Cambridge, Massachusetts, 02142,

United States

781 898 5627

Missing: Parthenon Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Parthenon Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Parthenon Therapeutics Patents

Parthenon Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Hepatotoxins
  • Indoles
patents chart

Application Date

Grant Date


Related Topics



Indoles, Hepatotoxins, Psychiatric diagnosis, Syndromes, Fluoroarenes


Application Date


Grant Date


Related Topics

Indoles, Hepatotoxins, Psychiatric diagnosis, Syndromes, Fluoroarenes



Latest Parthenon Therapeutics News

Parthenon doses first patient in Phase I trial of solid tumours treatment

Apr 27, 2023

Anti-tumour activity in select indications alone and in combination with anti-PD-1 inhibitors will be evaluated. PRTH-101 loosens collagen fibre alignment, allowing T-cells to enter and naturally attack the tumour. Credit: Giovanni Cancemi via Parthenon Therapeutics has dosed first patient in a Phase I clinical trial of PRTH-101 for the treatment of patients with immune-excluded solid tumours. Designed to assess the safety and tolerability of PRTH-101, the study will enrol up to 270 patients in the US with advanced or metastatic solid tumours. Anti-tumour activity in select indications alone and in combination with anti-PD-1 inhibitors will be evaluated in the dose escalation, multi-centre, open-label and dose expansion study. Preclinical models have demonstrated anti-tumor activity by targeting Discoidin Domain Receptor 1 (DDR1), a protein expressed on tumour cells that binds collagen. Parthenon Therapeutics chief medical officer J Paul Eder said: “The initiation of a Phase I trial for PRTH-101 is an important step forward for cancer patients with DDR1-associated tumours, immune-excluded solid tumours, that have been shown to respond poorly to existing immuno-therapies. “With no FDA-approved therapies that target DDR1- associated tumours, we believe that PRTH-101 could uniquely improve patient outcomes by breaking down the barrier that various types of tumours construct to protect them from immune attack. “Parthenon continues to focus on an unmet need in cancer that hasn’t been successfully targeted therapeutically, namely, direct modulation of the tumour microenvironment to overcome immune exclusion.” The trial will also evaluate DDR1 and pathway-related proteins as predictive biomarkers for patients whose tumours respond to treatment. Based on the Phase I clinical results, the company will determine dosing regimens for its Phase II clinical programme. DDR1 antagonist monoclonal antibody PRTH-101 loosens collagen fibres alignment and creates gaps in the tumour barrier, thereby allowing T-cells to enter and naturally attack the tumour. Share this article

Parthenon Therapeutics Frequently Asked Questions (FAQ)

  • When was Parthenon Therapeutics founded?

    Parthenon Therapeutics was founded in 2019.

  • Where is Parthenon Therapeutics's headquarters?

    Parthenon Therapeutics's headquarters is located at One Broadway, Cambridge.

  • What is Parthenon Therapeutics's latest funding round?

    Parthenon Therapeutics's latest funding round is Series A.

  • How much did Parthenon Therapeutics raise?

    Parthenon Therapeutics raised a total of $65M.

  • Who are the investors of Parthenon Therapeutics?

    Investors of Parthenon Therapeutics include Tekla Capital Management, Creacion Ventures, Alexandria Venture Investments, KdT Ventures, Northpond Ventures and 7 more.

  • Who are Parthenon Therapeutics's competitors?

    Competitors of Parthenon Therapeutics include Phenomic AI.

Compare Parthenon Therapeutics to Competitors


SYNSIGHT develops a drug discovery platform that provides molecular modeling, bioinformatics, and structural biology services enabling pharmaceutical and cosmetic industries to improve and accelerate their research.

Mestag Therapeutics Logo
Mestag Therapeutics

Mestag Therapeutics is an inflammatory disease and immuno-oncology company based in England. The company aims to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease.

Mestag Therapeutics

Mestag Therapeutics is an immunotherapy company. It harnesses new insights into fibroblast-immune cell interactions to develop treatments for cancer and inflammatory diseases. It was founded in 2020 and is based in Cambridge, United Kingdom.

Phenomic AI Logo
Phenomic AI

Phenomic AI is a biotechnology company. It develops medicines against the tumor stroma. It offers a platform that interrogates single-cell ribonucleic acid (RNA) data at scale. It uses advanced machine learning tools for processing imaging, ribonucleic acid (RNA) sequencing, and spatial transcriptomics data to understand the biology of single cells sitting in complex multi-cell systems. The company was founded in 2017 and is based in Toronto, Canada.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.